ClinicalTrials.gg
TerminatedNCT00496782Updated Jan 30, 2019Results posted

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

A Phase 1 interventional study of maraviroc and Trofile Assay and HIV RNA quantification assay in HIV Infections, sponsored by ViiV Healthcare. Terminated at 10 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Screening

Why this study was terminated
See Detailed Description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.

Enrollment
32nd of 44
16 · median 36
Started
2007
with 4 others
Phase 1
7 of 44
none open now
Registered
4th of 44
by date
Lead sponsor
8 of 44
ViiV Healthcare

Among the 44 studies testing maraviroc in HIV Infections, this one is the 32nd largest by enrollment, is one of 5 that started in 2007, is one of 7 in phase 1, and was the 4th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About maraviroc

Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing maraviroc in HIV Infections as a file.
02

Study summary

The purpose of this pilot study is to determine whether there is a correlation between viral load reduction (at Day 4, 7 or 14) following a short course (14 days) of Maraviroc added to a failing regimen, and the R5 result of the TrofileTM assay at screening.

Read the detailed description

The study A4001060 has been discontinued on April 22, 2008. A review of the poor rate of enrollment has projected difficulties in completing the study in a timely manner, despite the best efforts by the sponsor and the sites. Given the difficulties encountered in this pilot study and the need to conduct an even larger confirmatory study, the decision to discontinue the study has therefore been made. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Treatment Experienced
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 16 years of age (or minimum adult age as determined by local regulatory authorities or as dictated by local law) at the screening visit.
  • Have an RNA ≥ 1000 copies/mL, at screening.
  • Subjects receiving another antiretroviral compound through participation in a phase 3 or 4 clinical study are eligible to participate in this trial provided.
  • That the 2 investigational agents are required to offer the subject a regimen with 2 or 3 active antiretroviral drugs (i.e. one or fewer approved treatment is available to the subject due to prior resistance or intolerance),
  • Neither protocol prohibits the use of the other antiretroviral agent, AND the dosing of the two agents when used together is known AND a letter from the Pfizer clinical pharmacologists for maraviroc identifies the dose of maraviroc to be used with other investigational agents.
  • Based on screening genotypic resistance testing results the subject must be able to receive at least 3 active drugs other than maraviroc in the new OBT. This is defined as:
  • Having three drugs considered susceptible by genotype interpretation (if etravirine will be used, fewer than 3 etravirine resistance mutations will be taken as etravirine susceptibility); or,
  • Having two drugs considered susceptible by genotype interpretation (if etravirine will be used, fewer than 3 etravirine resistance mutations will be taken as etravirine susceptibility) and be willing to include raltegravir in the OBT not having used raltegravir in the past.

Exclusion criteria

Exclusion Criteria:

  • Potentially life threatening (Grade 4) laboratory abnormality or medical condition.
  • Severe hepatic impairment ( classification B or C).
  • End stage renal disease or other disease states requiring dialysis therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    Single

    Drug: maraviroc · Procedure: Trofile Assay and HIV RNA quantification assay

Interventions

  • Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.

  • ProcedureTrofile Assay and HIV RNA quantification assay

    Trofile Assay and HIV RNA quantification assay

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) With R5 & Non-R5 Tropism Results From the Trofile(tm) Assay

    Spearman's correlation coefficient to assess percentage of participants achieving HIV-1 RNA with tropism

    Time frame: Baseline, Day 4, 7, 14

Secondary outcomes

  1. Subjects Achieving HIV-1 RNA <400 Copies/mL

    Number of Subjects Achieving HIV-1 RNA \<400 Copies/mL at each time point

    Time frame: Days 4, 7, 14, 28, and Weeks 8, 12, 18, and 24

  2. Subjects Achieving HIV-1 RNA <50 Copies/mL

    Number of Subjects Achieving HIV-1 RNA \<50 Copies/mL at each time point

    Time frame: Days 4, 7, 14, 28, and Weeks 8, 12, 18, and 24

  3. Subjects With Virologic Failure

    For this protocol, virologic failure will be confirmed by a repeat viral load test within 2 weeks of first viral load meeting any of the following criteria: 1. Failing to achieve a reduction in HIV-1 RNA \> 0.5 log10 copies/mL from baseline by the second viral load determination (unless the viral load is below level of quantification \[LOQ\]); 2. Experiencing a \> 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline \> 0.5 log10 copies/mL; or 3. Experiencing an HIV-1 RNA \>1000 copies/mL after having achieved an HIV-1 RNA below LOQ.

    Time frame: Baseline up to Week 24

  4. Time to Virologic Failure

    For this protocol, virologic failure will be confirmed by a repeat viral load test within 2 weeks of first viral load meeting any of the following criteria: 1. Failing to achieve a reduction in HIV-1 RNA \> 0.5 log10 copies/mL from baseline by the second viral load determination (unless the viral load is below level of quantification \[LOQ\]); 2. Experiencing a \> 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline \> 0.5 log10 copies/mL; or 3. Experiencing an HIV-1 RNA \>1000 copies/mL after having achieved an HIV-1 RNA below LOQ.

    Time frame: Baseline up to Week 24

  5. Change in Lymphocyte Subset CD4 From Baseline

    Calculated average of CD4 at Day 7, 14, 28 and Week 24 minus CD4 at Day 1

    Time frame: Day 1 (Baseline), Day 7, 14, 28 and Weeks 24

  6. Change in Lymphocyte Subset CD8 From Day 1

    Calculated average of CD8 at Day 7, 14, 28 and Week 24 minus CD8 at Day 1

    Time frame: Day 1(Baseline), Day 7, 14, 28 and Weeks 24

  7. Change in Lymphocyte Subsets; CD4 and CD8 From Screening.

    Calculated avergae of {CD4 or CD8 at Day 1 - CD4 or CD8 at Screening}

    Time frame: Screening (Day -14 to 0), Day 1.

  8. Change in Detectable Tropism From Screening

    Number of subjects who switch their tropism status from screening to Baseline

    Time frame: Screening (Day -21 to 0), Baseline.

  9. Change in Detectable Tropism From Baseline

    Number of subjects who switch their tropism status from Baseline to Days 7, 14, and Week 24/End of Study(EOS)/Discontinuation

    Time frame: Baseline, Day 15 and Week 24/End of Study/Discontinuation

  10. Change in Detectable Resistance (Genotype) and Susceptibility (Phenotype) to Drugs in the Regimen From Screening

    Change in detectable resistance (genotype) and susceptibility (phenotype) to drugs in the regimen from Screening

    Time frame: Screening (Day -21), Baseline (Day 0), Day 14 (after addition of MVC to a failing regimen), Week 24, and time of Virologic Failure.

  11. Number of Subjects With Susceptibility to Maraviroc

    Phenotypic susceptibility to maraviroc

    Time frame: Screening (Day -21 to 0), Day 14, Week 24

  12. Change in Gene Sequence in Gp-160, and the V3 Loop From Screening Visit (Day -21 to 0) to Day 14, Time of Virologic Failure (See Section 6.5.1) and Week 24

    Change in gene sequence in gp-160, and the V3 loop from Screening visit (Day -21 to 0) to Day 14, time of virologic failure (See Section 6.5.1) and Week 24

    Time frame: Screening (Day -21 to 0), Day 14, time of virologic failure, and Week 24

  13. Correlation of Mutations in gp160 and the V3 Loop and Decreased Susceptibility to Maraviroc

    Time frame: Screening (Day -21 to 0), Day 14, time of virologic failure, Week 24

07

Results

Posted Mar 19, 2010
Limitations and caveats
Study terminated prematurely due to slow enrollment. Premature termination of study was not due to any safety concerns. Efficacy data not summarized due to low sample size; only safety was summarized.

Participant flow

Participant flow — Overall Study
MilestoneCCR5-Tropic HIV-1Non-CCR5-Tropic HIV-1
Started97
Completed85
Not completed12
Withdrew: Protocol violation12

Outcome measures

SecondarySubjects Achieving HIV-1 RNA <400 Copies/mL

Number of Subjects Achieving HIV-1 RNA \<400 Copies/mL at each time point

Time frame:
Days 4, 7, 14, 28, and Weeks 8, 12, 18, and 24

No measurements were reported for this outcome.

SecondarySubjects Achieving HIV-1 RNA <50 Copies/mL

Number of Subjects Achieving HIV-1 RNA \<50 Copies/mL at each time point

Time frame:
Days 4, 7, 14, 28, and Weeks 8, 12, 18, and 24

No measurements were reported for this outcome.

SecondarySubjects With Virologic Failure

For this protocol, virologic failure will be confirmed by a repeat viral load test within 2 weeks of first viral load meeting any of the following criteria: 1. Failing to achieve a reduction in HIV-1 RNA \> 0.5 log10 copies/mL from baseline by the second viral load determination (unless the viral load is below level of quantification \[LOQ\]); 2. Experiencing a \> 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline \> 0.5 log10 copies/mL; or 3. Experiencing an HIV-1 RNA \>1000 copies/mL after having achieved an HIV-1 RNA below LOQ.

Time frame:
Baseline up to Week 24

No measurements were reported for this outcome.

SecondaryTime to Virologic Failure

For this protocol, virologic failure will be confirmed by a repeat viral load test within 2 weeks of first viral load meeting any of the following criteria: 1. Failing to achieve a reduction in HIV-1 RNA \> 0.5 log10 copies/mL from baseline by the second viral load determination (unless the viral load is below level of quantification \[LOQ\]); 2. Experiencing a \> 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline \> 0.5 log10 copies/mL; or 3. Experiencing an HIV-1 RNA \>1000 copies/mL after having achieved an HIV-1 RNA below LOQ.

Time frame:
Baseline up to Week 24

No measurements were reported for this outcome.

SecondaryChange in Lymphocyte Subset CD4 From Baseline

Calculated average of CD4 at Day 7, 14, 28 and Week 24 minus CD4 at Day 1

Time frame:
Day 1 (Baseline), Day 7, 14, 28 and Weeks 24

No measurements were reported for this outcome.

PrimaryChange From Baseline in Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) With R5 & Non-R5 Tropism Results From the Trofile(tm) Assay

Spearman's correlation coefficient to assess percentage of participants achieving HIV-1 RNA with tropism

Time frame:
Baseline, Day 4, 7, 14

No measurements were reported for this outcome.

SecondaryChange in Lymphocyte Subset CD8 From Day 1

Calculated average of CD8 at Day 7, 14, 28 and Week 24 minus CD8 at Day 1

Time frame:
Day 1(Baseline), Day 7, 14, 28 and Weeks 24

No measurements were reported for this outcome.

SecondaryChange in Lymphocyte Subsets; CD4 and CD8 From Screening.

Calculated avergae of {CD4 or CD8 at Day 1 - CD4 or CD8 at Screening}

Time frame:
Screening (Day -14 to 0), Day 1.

No measurements were reported for this outcome.

SecondaryChange in Detectable Tropism From Screening

Number of subjects who switch their tropism status from screening to Baseline

Time frame:
Screening (Day -21 to 0), Baseline.

No measurements were reported for this outcome.

SecondaryChange in Detectable Tropism From Baseline

Number of subjects who switch their tropism status from Baseline to Days 7, 14, and Week 24/End of Study(EOS)/Discontinuation

Time frame:
Baseline, Day 15 and Week 24/End of Study/Discontinuation

No measurements were reported for this outcome.

SecondaryChange in Detectable Resistance (Genotype) and Susceptibility (Phenotype) to Drugs in the Regimen From Screening

Change in detectable resistance (genotype) and susceptibility (phenotype) to drugs in the regimen from Screening

Time frame:
Screening (Day -21), Baseline (Day 0), Day 14 (after addition of MVC to a failing regimen), Week 24, and time of Virologic Failure.

No measurements were reported for this outcome.

SecondaryNumber of Subjects With Susceptibility to Maraviroc

Phenotypic susceptibility to maraviroc

Time frame:
Screening (Day -21 to 0), Day 14, Week 24

No measurements were reported for this outcome.

SecondaryChange in Gene Sequence in Gp-160, and the V3 Loop From Screening Visit (Day -21 to 0) to Day 14, Time of Virologic Failure (See Section 6.5.1) and Week 24

Change in gene sequence in gp-160, and the V3 loop from Screening visit (Day -21 to 0) to Day 14, time of virologic failure (See Section 6.5.1) and Week 24

Time frame:
Screening (Day -21 to 0), Day 14, time of virologic failure, and Week 24

No measurements were reported for this outcome.

SecondaryCorrelation of Mutations in gp160 and the V3 Loop and Decreased Susceptibility to Maraviroc
Time frame:
Screening (Day -21 to 0), Day 14, time of virologic failure, Week 24

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CCR5-Tropic HIV-1—4/9 (44.4%)9/9 (100%)
Non-CCR5-Tropic HIV-1—0/7 (0%)4/7 (57.1%)
Most frequent serious events
Most frequent serious events
EventCCR5-Tropic HIV-1Non-CCR5-Tropic HIV-1
Myocardial InfarctionCardiac disorders1/90/7
OrchitisInfections and infestations1/90/7
PneumoniaInfections and infestations1/90/7
Testicular neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/90/7
HeadacheNervous system disorders1/90/7
SyncopeNervous system disorders1/90/7
Testicular swellingReproductive system and breast disorders1/90/7
Most frequent other events
Showing 10 of 29
Most frequent other events
EventCCR5-Tropic HIV-1Non-CCR5-Tropic HIV-1
Upper Respiratory Tract InfectionInfections and infestations3/90/7
Neuropathy peripheralNervous system disorders2/90/7
RashSkin and subcutaneous tissue disorders2/90/7
HeadacheNervous system disorders2/90/7
DiarrhoeaGastrointestinal disorders1/91/7
VomitingGastrointestinal disorders1/91/7
DizzinessNervous system disorders1/91/7
DyspepsiaGastrointestinal disorders0/91/7
NauseaGastrointestinal disorders0/91/7
Otitis ExternaInfections and infestations0/91/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)CCR5-Tropic HIV-1Non-CCR5-Tropic HIV-1Total
Mean46.3 ± 4.941.0 ± 4.844.0 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)CCR5-Tropic HIV-1Non-CCR5-Tropic HIV-1Total
Female112
Male8614
08

Study locations

10 sites
  • Pfizer Investigational Site
    Miami, Florida 33137, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60613, United States
  • Pfizer Investigational Site
    Topeka, Kansas 66606-1670, United States
  • Pfizer Investigational Site
    Topeka, Kansas 66606, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48202, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68198-5400, United States
  • Pfizer Investigational Site
    Buffalo, New York 14215, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74135, United States
  • Pfizer Investigational Site
    Hampton, Virginia 23666, United States
  • Pfizer Investigational Site
    Montreal, Quebec H2L 5B1, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2007
First posted
Jul 4, 2007
Start
Jul 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Mar 19, 2010
Last update
Jan 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00496782
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jul 4, 2007
Start date
Jul 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Mar 19, 2010
Last update
Jan 30, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion